[96a5a0]: / output / allTrials / identified / NCT00008073_identified.json

Download this file

370 lines (370 with data), 16.7 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
{
"info": {
"nct_id": "NCT00008073",
"official_title": "Phase I Study Of Octreotide Acetate (Sandostatin) (SMS) As A Biomodulator Of Doxorubicin (DOX)",
"inclusion_criteria": "Healthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "",
"miscellaneous_criteria": "DISEASE CHARACTERISTICS: Histologically confirmed malignancy ineligible for therapy of proven greater benefit than doxorubicin alone Measurable or evaluable disease\n\nPATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: WBC at least 3,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2 mg/dL SGOT no greater than 4 times normal Renal: Creatinine no greater than 2 mg/dL Cardiovascular: LVEF at least 50% No compensated or uncompensated congestive heart failure Other: Not pregnant Fertile patients must use effective contraception during and for 2 months after study No history of gallstones with gallbladder in place\n\nPRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics At least 3 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosourea) and recovered No more than 240 mg/m2 total cumulative dose of prior doxorubicin Endocrine therapy: Prior octreotide allowed Recovered from prior octreotide Radiotherapy: At least 3 weeks since prior radiotherapy and recovered Surgery: Not specified"
},
"inclusion_lines": [
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [],
"miscellaneous_lines": [
{
"line": "DISEASE CHARACTERISTICS: Histologically confirmed malignancy ineligible for therapy of proven greater benefit than doxorubicin alone Measurable or evaluable disease",
"criterions": [
{
"exact_snippets": "Histologically confirmed malignancy",
"criterion": "malignancy",
"requirements": [
{
"requirement_type": "confirmation",
"expected_value": "histologically confirmed"
}
]
},
{
"exact_snippets": "ineligible for therapy of proven greater benefit than doxorubicin alone",
"criterion": "eligibility for therapy",
"requirements": [
{
"requirement_type": "eligibility",
"expected_value": "ineligible for therapy of proven greater benefit than doxorubicin alone"
}
]
},
{
"exact_snippets": "Measurable or evaluable disease",
"criterion": "disease measurability",
"requirements": [
{
"requirement_type": "measurability",
"expected_value": [
"measurable",
"evaluable"
]
}
]
}
]
},
{
"line": "PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: WBC at least 3,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2 mg/dL SGOT no greater than 4 times normal Renal: Creatinine no greater than 2 mg/dL Cardiovascular: LVEF at least 50% No compensated or uncompensated congestive heart failure Other: Not pregnant Fertile patients must use effective contraception during and for 2 months after study No history of gallstones with gallbladder in place",
"criterions": [
{
"exact_snippets": "Age: 18 and over",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum age",
"expected_value": true
},
{
"requirement_type": "age",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
},
{
"exact_snippets": "Performance status: ECOG 0-2",
"criterion": "performance status",
"requirements": [
{
"requirement_type": "scale",
"expected_value": "ECOG"
},
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "N/A"
},
{
"operator": "<=",
"value": 2,
"unit": "N/A"
}
]
}
}
]
},
{
"exact_snippets": "Life expectancy: Not specified",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "specification",
"expected_value": "Not specified"
}
]
},
{
"exact_snippets": "Hematopoietic: WBC at least 3,500/mm3",
"criterion": "WBC",
"requirements": [
{
"requirement_type": "minimum count",
"expected_value": {
"operator": ">=",
"value": 3500,
"unit": "mm3"
}
}
]
},
{
"exact_snippets": "Platelet count at least 100,000/mm3",
"criterion": "platelet count",
"requirements": [
{
"requirement_type": "minimum count",
"expected_value": {
"operator": ">=",
"value": 100000,
"unit": "mm3"
}
}
]
},
{
"exact_snippets": "Hepatic: Bilirubin no greater than 2 mg/dL",
"criterion": "bilirubin",
"requirements": [
{
"requirement_type": "maximum level",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "mg/dL"
}
}
]
},
{
"exact_snippets": "SGOT no greater than 4 times normal",
"criterion": "SGOT",
"requirements": [
{
"requirement_type": "maximum level",
"expected_value": "no greater than 4 times normal"
}
]
},
{
"exact_snippets": "Renal: Creatinine no greater than 2 mg/dL",
"criterion": "creatinine",
"requirements": [
{
"requirement_type": "maximum level",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "mg/dL"
}
}
]
},
{
"exact_snippets": "Cardiovascular: LVEF at least 50%",
"criterion": "LVEF",
"requirements": [
{
"requirement_type": "minimum percentage",
"expected_value": {
"operator": ">=",
"value": 50,
"unit": "%"
}
}
]
},
{
"exact_snippets": "No compensated or uncompensated congestive heart failure",
"criterion": "congestive heart failure",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Not pregnant",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "status",
"expected_value": false
}
]
},
{
"exact_snippets": "Fertile patients must use effective contraception during and for 2 months after study",
"criterion": "contraception",
"requirements": [
{
"requirement_type": "usage",
"expected_value": "effective contraception during and for 2 months after study"
}
]
},
{
"exact_snippets": "No history of gallstones with gallbladder in place",
"criterion": "history of gallstones with gallbladder in place",
"requirements": [
{
"requirement_type": "history",
"expected_value": false
}
]
}
]
},
{
"line": "PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics At least 3 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosourea) and recovered No more than 240 mg/m2 total cumulative dose of prior doxorubicin Endocrine therapy: Prior octreotide allowed Recovered from prior octreotide Radiotherapy: At least 3 weeks since prior radiotherapy and recovered Surgery: Not specified",
"criterions": [
{
"exact_snippets": "At least 3 weeks since prior chemotherapy",
"criterion": "time since prior chemotherapy",
"requirements": [
{
"requirement_type": "time since",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "6 weeks for mitomycin or nitrosourea",
"criterion": "time since prior mitomycin or nitrosourea",
"requirements": [
{
"requirement_type": "time since",
"expected_value": {
"operator": ">=",
"value": 6,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "recovered",
"criterion": "recovery from prior chemotherapy",
"requirements": [
{
"requirement_type": "recovery status",
"expected_value": true
}
]
},
{
"exact_snippets": "No more than 240 mg/m2 total cumulative dose of prior doxorubicin",
"criterion": "total cumulative dose of prior doxorubicin",
"requirements": [
{
"requirement_type": "dose",
"expected_value": {
"operator": "<=",
"value": 240,
"unit": "mg/m2"
}
}
]
},
{
"exact_snippets": "Prior octreotide allowed",
"criterion": "prior octreotide",
"requirements": [
{
"requirement_type": "allowance",
"expected_value": true
}
]
},
{
"exact_snippets": "Recovered from prior octreotide",
"criterion": "recovery from prior octreotide",
"requirements": [
{
"requirement_type": "recovery status",
"expected_value": true
}
]
},
{
"exact_snippets": "At least 3 weeks since prior radiotherapy",
"criterion": "time since prior radiotherapy",
"requirements": [
{
"requirement_type": "time since",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "recovered",
"criterion": "recovery from prior radiotherapy",
"requirements": [
{
"requirement_type": "recovery status",
"expected_value": true
}
]
}
]
}
],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}